Clinical Feasibility of Long-Read WGS for DNA Methylation Signature Analysis
Clinical Snapshot
PICO Framework
| P — Population | Two individuals with pathogenic KMT2D variants (Kabuki syndrome) |
| I — Intervention | Long-read sequencing (PacBio and Oxford Nanopore Technologies) for DNA methylation analysis |
| C — Comparator | DNA methylation arrays (standard reference method) |
| O — Outcomes | Diagnostic accuracy of methylation signature classification, concordance between platforms, clinical feasibility |
Bottom Line
This proof-of-concept study demonstrates technical feasibility of using long-read sequencing for DNA methylation signature analysis in two patients with KMT2D variants. While the results show perfect concordance with established array-based methods, the extremely small sample size (n=2) severely limits clinical interpretation and generalizability. The study lacks essential diagnostic accuracy metrics including sensitivity, specificity, and confidence intervals. Although the technology offers theoretical advantages including simultaneous sequence and methylation analysis, robust validation studies with larger, diverse patient cohorts are essential before clinical implementation. The current evidence is insufficient to support routine clinical adoption, despite the promising technological approach.
Key Findings
P Value: Not provided
Effect Size: 100% concordance reported (2/2 samples correctly classified)
Primary Outcome: Concordance between long-read sequencing and array-based methylation signatures
Nnt Or Sensitivity: Sensitivity and specificity cannot be calculated from available data
Confidence Interval: Not provided
Clinical Application
Technology platforms available but require significant infrastructure investment and specialized expertise Long-read sequencing platforms available in major Australian pathology services; would require TGA approval for diagnostic use and PBS consideration for funding Patients suspected of rare genetic disorders with known methylation signatures, particularly Kabuki syndrome
Abstract
DNA methylation (DNAm) signatures have emerged as valuable diagnostic biomarkers for rare genetic disorders. To date, the most widely used approach for establishing and validating these signatures has relied on array-based technologies. However, in clinical diagnostics, there is a growing shift from short-read sequencing (SRS) toward long-read sequencing (LRS) technologies. Recent advances in platforms such as Pacific Biosciences (PacBio) and Oxford Nanopore Technologies (ONT) enable direct assessment of DNAm from native DNA, offering improved resolution and reduced technical bias compared to array-based technologies. In this study, we compared DNAm profiles generated by LRS with those obtained from DNAm arrays. DNAm profiles of two individuals with pathogenic KMT2D variants were analyzed using DNAm arrays, LRS using PacBio and ONT, and ONT multiplexed sequencing with adaptive sampling. A support vector machine (SVM) classifier trained on array data, as well as the public classification platform EpigenCentral, yielded correct predictions for all LRS samples, underscoring the potential of LRS platforms in DNAm-based diagnostics. Our results suggest that DNAm profiles generated by LRS align well with DNAm signatures established using DNAm arrays, supporting their feasibility in clinical and research applications with the added benefit of simultaneous methylation and sequence analysis.
References
- 1.Hildonen, M., Mariani, L., Dalsberg, J., Bak, M., Weksberg, R., Choufani, S., & Tümer, Z. (2026). Clinical feasibility of long-read WGS for DNA methylation signature analysis. Clinical Genetics. https://doi.org/10.1111/cge.70108
Related Research
Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
Genetics versus environment in the pathophysiology of sagittal synostosis
19 July 2026
Nucleic acids research
FABIAN-variant 2026: improved prediction of the effects of DNA variants on transcription factor binding
13 July 2026
BioEssays : news and reviews in molecular, cellular and developmental biology
AI in Genomics: From Variant Calling to Multi-Omics Integration
3 July 2026
This content is for educational purposes for healthcare professionals only and does not constitute clinical advice. Clinical decisions should be based on individual patient assessment, current guidelines, and appropriate specialist consultation. Editorial Standards · Privacy Policy · Terms of Service